Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 5/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
| ▸ | AGTR1 | P30556 | 9/20 | 0.34 |
| ▸ | AGTR2 | P50052 | 8/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1888747 | 0.91 | PPARG (0.37) | PPARGAGTR1AGTR2 | |
| SCHEMBL13368323 | 0.90 | PPARG (0.39) | PPARGGRIN1GRIN2BMAPK14AGTR1 | |
| SCHEMBL1889960 | 0.84 | PPARG (0.40) | PPARGGRIN1GRIN2BMAPK14AGTR1 | |
| SCHEMBL1891901 | 0.83 | AGTR1 (0.39) | PPARGAGTR1AGTR2 | |
| SCHEMBL1894764 | 0.83 | PPARG (0.39) | PPARGGRIN1GRIN2BMAPK14AGTR1 | |
| SCHEMBL1899885 | 0.81 | PPARG (0.42) | PPARGMAPK14AGTR1AGTR2 | |
| SCHEMBL12357042 | 0.80 | PPARG (0.41) | PPARGAGTR1AGTR2 | |
| SCHEMBL2842851 | 0.77 | AGTR1 (0.44) | PPARGAGTR1AGTR2 | |
| SCHEMBL4011619 | 0.77 | AGTR1 (0.42) | PPARGAGTR1AGTR2 | |
| SCHEMBL1890409 | 0.76 | PPARG (0.46) | PPARGGRIN1GRIN2BMAPK14AGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113780-A1 | HETEROMONOCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113780-A1 | HETEROMONOCYCLIC COMPOUND AND USE THEREOF | C1R, C1S, C3AR1 | PPARG 3043/4885GRIN1 409/4885GRIN2B 850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.